Thomas Shrader
Stock Analyst at BTIG
(1.64)
# 3,146
Out of 4,736 analysts
42
Total ratings
39.47%
Success rate
-4.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALEC Alector | Maintains: Buy | $16 → $5 | $1.73 | +189.02% | 2 | Nov 26, 2024 | |
| ATHA Athira Pharma | Downgrades: Neutral | n/a | $0.54 | - | 3 | Sep 4, 2024 | |
| PCVX Vaxcyte | Maintains: Buy | $98 → $160 | $88.17 | +81.47% | 2 | Sep 3, 2024 | |
| OVID Ovid Therapeutics | Maintains: Buy | $11 → $5 | $0.70 | +616.13% | 2 | Jun 18, 2024 | |
| ACIU AC Immune | Initiates: Buy | $8 | $2.65 | +201.89% | 1 | May 31, 2024 | |
| PMN ProMIS Neurosciences | Initiates: Buy | $8 | $0.99 | +708.98% | 1 | Oct 3, 2023 | |
| DTIL Precision BioSciences | Maintains: Buy | $180 → $60 | $4.56 | +1,215.79% | 1 | Jul 28, 2023 | |
| BHVN Biohaven | Reiterates: Buy | $24 | $39.03 | -38.51% | 2 | Jun 6, 2023 | |
| ANNX Annexon | Maintains: Buy | $15 → $7 | $4.17 | +67.87% | 2 | May 25, 2023 | |
| COYA Coya Therapeutics | Initiates: Buy | $15 | $5.66 | +165.02% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $0.51 | +2,474.26% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $31 | $53.50 | -42.06% | 3 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $2.18 | +358.72% | 2 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $1.63 | +1,249.69% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $14 | $6.53 | +114.56% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $11.07 | +360.70% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.58 | +520.16% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.22 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $23.04 | - | 2 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $58 | $6.58 | +781.46% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $2.96 | +1.35% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $140.98 | +145.42% | 3 | Feb 21, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.21 | - | 1 | Jun 30, 2017 |
Alector
Nov 26, 2024
Maintains: Buy
Price Target: $16 → $5
Current: $1.73
Upside: +189.02%
Athira Pharma
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.54
Upside: -
Vaxcyte
Sep 3, 2024
Maintains: Buy
Price Target: $98 → $160
Current: $88.17
Upside: +81.47%
Ovid Therapeutics
Jun 18, 2024
Maintains: Buy
Price Target: $11 → $5
Current: $0.70
Upside: +616.13%
AC Immune
May 31, 2024
Initiates: Buy
Price Target: $8
Current: $2.65
Upside: +201.89%
ProMIS Neurosciences
Oct 3, 2023
Initiates: Buy
Price Target: $8
Current: $0.99
Upside: +708.98%
Precision BioSciences
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $4.56
Upside: +1,215.79%
Biohaven
Jun 6, 2023
Reiterates: Buy
Price Target: $24
Current: $39.03
Upside: -38.51%
Annexon
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $4.17
Upside: +67.87%
Coya Therapeutics
May 18, 2023
Initiates: Buy
Price Target: $15
Current: $5.66
Upside: +165.02%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $0.51
Upside: +2,474.26%
Mar 20, 2023
Maintains: Buy
Price Target: $26 → $31
Current: $53.50
Upside: -42.06%
Nov 14, 2022
Maintains: Buy
Price Target: $30 → $10
Current: $2.18
Upside: +358.72%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $1.63
Upside: +1,249.69%
May 24, 2022
Maintains: Buy
Price Target: $31 → $14
Current: $6.53
Upside: +114.56%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $11.07
Upside: +360.70%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $2.58
Upside: +520.16%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $5.22
Upside: -
Oct 16, 2020
Downgrades: Neutral
Price Target: n/a
Current: $23.04
Upside: -
Sep 15, 2020
Maintains: Buy
Price Target: $51 → $58
Current: $6.58
Upside: +781.46%
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $2.96
Upside: +1.35%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $140.98
Upside: +145.42%
Jun 30, 2017
Downgrades: Hold
Price Target: n/a
Current: $0.21
Upside: -